Annual FCF
-$12.27 M
+$12.74 M+50.94%
December 31, 2023
Summary
- As of February 21, 2025, APRE annual free cash flow is -$12.27 million, with the most recent change of +$12.74 million (+50.94%) on December 31, 2023.
- During the last 3 years, APRE annual FCF has risen by +$29.56 million (+70.66%).
Performance
APRE Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$2.47 M
+$1.18 M+32.36%
September 30, 2024
Summary
- As of February 21, 2025, APRE quarterly free cash flow is -$2.47 million, with the most recent change of +$1.18 million (+32.36%) on September 30, 2024.
- Over the past year, APRE quarterly FCF has increased by +$1.48 million (+37.41%).
- APRE quarterly FCF is now -6.03% below its all-time high of -$2.33 million, reached on September 30, 2023.
Performance
APRE Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$13.81 M
-$140.40 K-1.03%
September 30, 2024
Summary
- As of February 21, 2025, APRE TTM free cash flow is -$13.81 million, with the most recent change of -$140.40 thousand (-1.03%) on September 30, 2024.
- Over the past year, APRE TTM FCF has dropped by -$572.60 thousand (-4.33%).
- APRE TTM FCF is now -228.98% below its all-time high of -$4.20 million, reached on March 31, 2019.
Performance
APRE TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
APRE Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +50.9% | +37.4% | -4.3% |
| 3 y3 years | +70.7% | +70.0% | +66.1% |
| 5 y5 years | +19.6% | +12.0% | +48.4% |
APRE Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +67.4% | -6.0% | +75.8% | -12.5% | +63.4% |
| 5 y | 5-year | at high | +70.7% | -6.0% | +83.3% | -12.5% | +69.8% |
| alltime | all time | <-9999.0% | +70.7% | -6.0% | +83.3% | -229.0% | +69.8% |
Aprea Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.47 M(-32.4%) | -$13.81 M(+1.0%) |
| Jun 2024 | - | -$3.65 M(-7.5%) | -$13.67 M(+3.3%) |
| Mar 2024 | - | -$3.94 M(+5.3%) | -$13.24 M(+7.9%) |
| Dec 2023 | -$12.27 M(-50.9%) | -$3.75 M(+61.0%) | -$12.27 M(-2.2%) |
| Sep 2023 | - | -$2.33 M(-27.6%) | -$12.54 M(-25.4%) |
| Jun 2023 | - | -$3.22 M(+8.0%) | -$16.81 M(-25.3%) |
| Mar 2023 | - | -$2.98 M(-25.9%) | -$22.49 M(-10.1%) |
| Dec 2022 | -$25.01 M(-33.6%) | -$4.02 M(-39.0%) | -$25.01 M(-19.8%) |
| Sep 2022 | - | -$6.59 M(-25.9%) | -$31.17 M(-5.0%) |
| Jun 2022 | - | -$8.90 M(+62.0%) | -$32.81 M(+3.6%) |
| Mar 2022 | - | -$5.50 M(-46.0%) | -$31.66 M(-16.0%) |
| Dec 2021 | -$37.69 M | -$10.18 M(+23.6%) | -$37.69 M(-7.5%) |
| Sep 2021 | - | -$8.23 M(+6.2%) | -$40.72 M(-7.3%) |
| Jun 2021 | - | -$7.75 M(-32.7%) | -$43.91 M(-4.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$11.52 M(-12.8%) | -$45.80 M(+9.5%) |
| Dec 2020 | -$41.83 M(+56.4%) | -$13.22 M(+15.7%) | -$41.83 M(-3.6%) |
| Sep 2020 | - | -$11.42 M(+18.5%) | -$43.37 M(+24.8%) |
| Jun 2020 | - | -$9.64 M(+27.6%) | -$34.75 M(+15.5%) |
| Mar 2020 | - | -$7.55 M(-48.8%) | -$30.10 M(+12.6%) |
| Dec 2019 | -$26.74 M(+75.3%) | -$14.76 M(+426.4%) | -$26.74 M(+123.2%) |
| Sep 2019 | - | -$2.80 M(-43.7%) | -$11.98 M(+30.5%) |
| Jun 2019 | - | -$4.98 M(+18.7%) | -$9.18 M(+118.7%) |
| Mar 2019 | - | -$4.20 M | -$4.20 M |
| Dec 2018 | -$15.25 M(+8.9%) | - | - |
| Dec 2017 | -$14.00 M(+637.8%) | - | - |
| Jun 2008 | -$1.90 M(+49.0%) | - | - |
| Jun 2007 | -$1.27 M(-36.9%) | - | - |
| Jun 2006 | -$2.02 M(<-9900.0%) | - | - |
| Dec 2004 | $0.00 | - | - |
FAQ
- What is Aprea Therapeutics annual free cash flow?
- What is the all time high annual FCF for Aprea Therapeutics?
- What is Aprea Therapeutics annual FCF year-on-year change?
- What is Aprea Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Aprea Therapeutics?
- What is Aprea Therapeutics quarterly FCF year-on-year change?
- What is Aprea Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Aprea Therapeutics?
- What is Aprea Therapeutics TTM FCF year-on-year change?
What is Aprea Therapeutics annual free cash flow?
The current annual FCF of APRE is -$12.27 M
What is the all time high annual FCF for Aprea Therapeutics?
Aprea Therapeutics all-time high annual free cash flow is $0.00
What is Aprea Therapeutics annual FCF year-on-year change?
Over the past year, APRE annual free cash flow has changed by +$12.74 M (+50.94%)
What is Aprea Therapeutics quarterly free cash flow?
The current quarterly FCF of APRE is -$2.47 M
What is the all time high quarterly FCF for Aprea Therapeutics?
Aprea Therapeutics all-time high quarterly free cash flow is -$2.33 M
What is Aprea Therapeutics quarterly FCF year-on-year change?
Over the past year, APRE quarterly free cash flow has changed by +$1.48 M (+37.41%)
What is Aprea Therapeutics TTM free cash flow?
The current TTM FCF of APRE is -$13.81 M
What is the all time high TTM FCF for Aprea Therapeutics?
Aprea Therapeutics all-time high TTM free cash flow is -$4.20 M
What is Aprea Therapeutics TTM FCF year-on-year change?
Over the past year, APRE TTM free cash flow has changed by -$572.60 K (-4.33%)